Introduction {#s1}
============

Inadequate healing of myocardial infarction may contribute to local expansion of the infarct, frequently leading to chamber dilation, heart failure, or myocardial rupture \[1\]. Experimental evidence in mouse models suggests that Factor XIII might play a key role in wound healing and low persistent values lead to increased incidence of cardiac rupture following myocardial infarction. For example in heterozygous FXIII deficient mice (characterized by 50% plasma levels of FXIII) 100% die from cardiac rupture following MI ([Figure 1 A--C](#pone-0000048-g001){ref-type="fig"}) and FXIII replacement therapy reverts these findings \[2\]. Here we would like to share our initial clinical experiences with strikingly similar observations in patients with this grave disease.

![**A:** Short axis high resolution, high field cardiac MRI of a FXIII^−/−^ mouse 2 days after coronary ligation.\
Arrows: intrathoracic hematoma adjacent to experimental anterolateral infarction.\
**B:** Autopsy confirms a blood clot (asterisk) originating from myocardial rupture at the border zone (arrow) of the myocardial infarct.\
**C:** Histology of 1A shows rupture channel (arrows), filled with blood.\
**D:** In patients with ruptured MI, FXIII levels were significantly reduced (\*p\<0.01).\
**E:** Color Doppler echo of patient with new ventricular septum defect 7 days after myocardial infarction (arrow).\
**F:** MRI after VSD repair with patch (arrows).\
**G--I:** Explantation site of saphenous veins for CABG surgery displays delayed healing.\
**J:** 73 days after initial surgery, 3 revisions and 2 weeks after i.v. FXIII augmentation, the wound is closed.](pone.0000048.g001){#pone-0000048-g001}

Results and Discussion {#s2}
======================

We investigated FXIII levels in three consecutive patients presenting with acute myocardial rupture following myocardial infarction. FXIII levels in these patients were only 57±8% of normal ([Figure 1 D](#pone-0000048-g001){ref-type="fig"}), whereas all other coagulation tests were normal or not consistently altered. One patient suffered a rupture of the ventricular septum 7 days following MI, presenting with sudden onset of cardiogenic shock and a new systolic heart murmur. The diagnosis was confirmed by Doppler ([Figure 1 E](#pone-0000048-g001){ref-type="fig"}). Cardiac catheterization showed a shunt volume of 66% and severe coronary artery disease. Therefore, surgical closure of the 2 cm VSD ([Figure 1 F](#pone-0000048-g001){ref-type="fig"}) was combined with coronary artery bypass grafting utilizing the patient's saphenous veins. Six days later the patient presented again in cardiogenic shock, this time from a ruptured papillary muscle causing severe mitral valve insufficiency. The valve was replaced on the same day. Healing of the thoracotomy wound and lower extremity incisions was delayed for over 2 months ([Figure 1 G--I](#pone-0000048-g001){ref-type="fig"}), necessitating 3 surgical revisions. Repetitive swabs excluded infection, and the patient was not diabetic. During this time, FXIII levels were consistently reduced to 50%. Following the third revision, we initiated intravenous FXIII supplementation therapy (Fibrogammin 1,250 IE) and the skin wounds healed two weeks later ([Figure 1 J](#pone-0000048-g001){ref-type="fig"}). The other two patients died within 2 weeks after admission in cardiogenic shock.

To determine whether a truly causative relationship existed between FXIII activity and myocardial healing, we have recently studied myocardial repair in FXIII deficient mice \[2\]. All FXIII^−/−^ and FXIII^−/+^ mice died within 5 days after MI from left ventricular (LV) rupture and had locally reduced levels of FXIII as determined by imaging \[2\]. In contradistinction, FXIII^−/−^ that received 5 days of FXIII replacement therapy had normal survival rates, although cardiac MRI demonstrated worse LV remodeling in these reconstituted FXIII^−/−^. Likewise, skin healing was impaired in the same mouse model \[3\]. In conclusion, the reported clinical experiences and the parallel experimental data support the hypothesis that FXIII deficiency may impair healing in patients with MI while replacement therapy may alleviate complications. A prospective study is warranted to determine the clinical significance of these findings.
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